CHAMP STUDY SIMULATIONS: PICK THE WINNER. Elizabeth Zahn 19 May 2014

Similar documents
Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine

Supplementary Appendix

6/2/2017. CHAMP Trial: Design, Outcomes, Context, and Lessons Learned. Disclosures. Outline

Cinnarizine versus Topiramate in Prophylaxis of Migraines among Children and Adolescents: A Randomized, Double-Blind Clinical Trial

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.

Evidence Based Practice

Statistics for Clinical Trials: Basics of Phase III Trial Design

Why does my child hurt? How can we reduce the burden of headache? What is the burden of headache?

Lecture 2. Key Concepts in Clinical Research

Perspectives on PFO Closure: Clinical Trials for Stroke Prevention and Migraines

115 remained abstinent. 140 remained abstinent. Relapsed Remained abstinent Total

CHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials

Design of Experiments & Introduction to Research

aps/stone U0 d14 review d2 teacher notes 9/14/17 obj: review Opener: I have- who has

Efficient analysis of ordinal functional outcome scales

Homework Answers. 1.3 Data Collection and Experimental Design

Adolescent Migraine Treatment O F A

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis

PhD Course in Biostatistics

BMS for the Acute Treatment of Migraine: A Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Trial

Observational study is a poor way to gauge the effect of an intervention. When looking for cause effect relationships you MUST have an experiment.

Supplementary Online Content

Design and analysis of clinical trials

Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs

Disclosures. Triptans for Kids 5/16/13

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Quantifying the clinical measure of interest in the presence of missing data:

AP Statistics Exam Review: Strand 2: Sampling and Experimentation Date:

2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume:

Hans Hockey & Kristian Brock Biometrics Matters Ltd, Hamilton, NZ & Cancer Research UK Clinical Trials Unit, Birmingham, UK

A case study design of adaptive dose selection in a combined Phase II/III clinical trial. Junliang Chen, Ph.D November 18, 2016

Reflection Questions for Math 58B

Design for Targeted Therapies: Statistical Considerations

Module 5. The Epidemiological Basis of Randomised Controlled Trials. Landon Myer School of Public Health & Family Medicine, University of Cape Town

Scottish Medicines Consortium

Optimizing Communication of Emergency Response Adaptive Randomization Clinical Trials to Potential Participants

Common Statistical Issues in Biomedical Research

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

WATCHMAN PROTECT AF Study Rev. 6

The Loss of Heterozygosity (LOH) Algorithm in Genotyping Console 2.0

BIOE 301. Lecture Seventeen

Statistical Analysis Plan

Statistical Topic: Ethics and Trial Design*

P. 266 #9, 11. p. 289 # 4, 6 11, 14, 17

Supplementary Appendix

Experimental Design. Terminology. Chusak Okascharoen, MD, PhD September 19 th, Experimental study Clinical trial Randomized controlled trial

Glossary From Running Randomized Evaluations: A Practical Guide, by Rachel Glennerster and Kudzai Takavarasha

Botulinum toxin type A for the prevention of headaches in adults with chronic migraine


Statistical considerations in indirect comparisons and network meta-analysis

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

Evidence- and Value-based Solutions for Health Care Clinical Improvement Consults, Content Development, Training & Seminars, Tools

Rolling Dose Studies

Challenges in the Design and Analysis of Non-Inferiority Trials: A Case Study. Key Points from FDA Guidance

Chronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

1/25/2018 ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Disclosures: Objectives: Headache Division

Critical Review Form Clinical Prediction or Decision Rule

In this second module in the clinical trials series, we will focus on design considerations for Phase III clinical trials. Phase III clinical trials

Journal Club. 1. Develop a PICO (Population, Intervention, Comparison, Outcome) question for this study

Randomization: Too Important to Gamble with

SHORTENING TIMELINES AND IMPROVING EFFICIENCY IN DRUG DEVELOPMENT -Seamless drug development paradigms

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:

04/12/2014. Research Methods in Psychology. Chapter 6: Independent Groups Designs. What is your ideas? Testing

RANDOMIZED CLINICAL TRIALS. Study Designs. Randomized Clinical Trials (RCT) ASSIGN EXPOSURE Follow up Check for OUTCOME. Experimental studies

Sawtooth Software. The Number of Levels Effect in Conjoint: Where Does It Come From and Can It Be Eliminated? RESEARCH PAPER SERIES

Technology appraisal guidance Published: 23 February 2011 nice.org.uk/guidance/ta214

Randomized Clinical Trials

2.0 Synopsis. ABT-358 M Clinical Study Report R&D/06/099. (For National Authority Use Only) to Item of the Submission: Volume:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Synopsis (C1034T02) CNTO 95 Module 5.3 Clinical Study Report C1034T02

Suicidal Ideation & Behavior Discussion. Roger E. Meyer, MD Professor of Psychiatry Penn State Hershey Medical Center

Clinical Trials. Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany

Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009

Lasmiditan (200 mg and 100 mg) Compared to Placebo for Acute Treatment of Migraine

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:

Joseph W Hogan Brown University & AMPATH February 16, 2010

Pimavanserin Top-Line Results Phase III Parkinson s Disease Psychosis Trial (-020 Study) Creating the Next Generation of CNS Drugs

Research and Evaluation Methodology Program, School of Human Development and Organizational Studies in Education, University of Florida

Intro to Hypothesis Testing Exercises

Session 7: The Sliding Dichotomy 7.1 Background 7.2 Principles 7.3 Hypothetical example 7.4 Implementation 7.5 Example: CRASH Trial

2. SYNOPSIS Name of Sponsor/Company:

Fundamental Clinical Trial Design

SPARRA Mental Disorder: Scottish Patients at Risk of Readmission and Admission (to psychiatric hospitals or units)

Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

The Journal of Headache and Pain. Francesca Puledda 1*, Peter J. Goadsby 1 and Prab Prabhakar 2

Study No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):

Study No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122

Issues to Consider in the Design of Randomized Controlled Trials

Study Designs. Randomized Clinical Trials (RCT) RCT: Example 1. RCT: Two by Two Table. Outcome. Exposure. Yes a b No c d

The Simulacrum. What is it, how is it created, how does it work? Michael Eden on behalf of Sally Vernon & Cong Chen NAACCR 21 st June 2017

CHAPTER 5: PRODUCING DATA

Domenic J. Reda, MS, PhD Director Hines Cooperative Studies Program Coordinating Center US Dept of Veterans Affairs

How to Randomise? (Randomisation Design)

6/2/2017. Objectives. Statement of Problem: Migraine Headaches Are Common. Chronic Headache In Pediatrics, Botox and Beyond

Antihypertensive Trial Design ALLHAT

Technology appraisal guidance Published: 27 June 2012 nice.org.uk/guidance/ta260

Transcription:

CHAMP STUDY SIMULATIONS: PICK THE WINNER Elizabeth Zahn 19 May 2014

2 Outline Introduction Design Endpoints Pick the Winner Simulation Results

3 CHAMP Study: Introduction CHAMP = Childhood and Adolescent Migraine Prevention Study PI s: Dr. Andrew Hershey and Dr. Scott Powers Global objective: to determine the optimal treatment for the prevention of migraines in children and adolescents First trial of it s kind in this study population

4 CHAMP Study: Design Phase III intent-to-treat, 3-arm, multi-center, randomized, double-blind, placebo controlled safety and efficacy study 675 subjects, 8 to 17 years old 2:2:1 Randomization Stratified by age and headache frequency 2 drugs: Amitriptyline and Topiramate 3 trials in 1 Amitriptyline vs. placebo Topiramate vs. placebo Amitriptyline vs. Topiramate

5 CHAMP Study: Endpoints Primary endpoint: 50% reduction in migraine frequency per month Powered to detect 20% improvement for each treatment vs. placebo 15% difference in comparative effectiveness portion Secondary endpoint: migraine-related disability (PedMIDAS) Tertiary endpoint: tolerability Treatment groups differ on occurrence of SAEs Have a drop-out rate greater than 35% or worse than other therapy

6 CHAMP Study: Endpoints Cont. Primary endpoint assessed using logistic regression model Estimate log-odds of primary endpoint success for each treatment group Adjusted for stratification variables Age and headache frequency at baseline Three pair-wise treatment comparisons: AMI vs. PBO AMI vs. TPM TPM vs. PBO Bonferroni corrected significance level of 0.017 = (0.05/3)

7 Pick the Winner 3 Tiered approach 4 Possible practice recommendations: AMI because it is superior to PBO and TPM on primary outcome TPM because it is superior to PBO and AMI on primary outcome Both are possible first choice and tie-breaker is secondary outcome If no difference in secondary outcome, go to tertiary outcome Neither as first choice if neither are superior to placebo

8 Simulation Study Designed to assess the likelihood of picking the correct winning treatment Actual power can be thought of as making a correct decision using decision algorithm Uses 1 st tier of decision algorithm

9 Simulation Study Steps: Determine plausible range of values for true response rate for each treatment PBO + Response Rates: 40%, 45%, 50%, 55% AMI + Response Rates: 50%, 60%, 70%, 80% TPM + Response Rates: 50%, 70%, 85%, 95% 4*4*4 = 64 conditions For each condition, one of the 4 possible decisions was reached 10,000 replications for each condition

10 Simulation Results Probability of picking correct winner Number of conditions >80% 50%-80% <50% 57 4 3

11 Notable Results Condition 33: 50% PBO, 50% AMI, 50% TPM Provides assurance that decision algorithm maintains type 1 error level at or below 0.05 Individual Trials Decision Power Power: AMI vs. PBO Power: TPM vs. PBO Power: AMI vs. TPM Correct Winner AMI Better TPM Better Both None Prob. of Picking Winner Prob. of Picking Correct Winner 0.7% 0.9% 1.7% None 1.4% 1.4% 0.2% 97% 3% 97%

12 Notable Results Condition 43: 50% PBO, 70% AMI, 85% TPM Used to choose sample size for each primary hypothesis Study would have ~100% power to correctly select TPM Individual Trials Decision Power Power: AMI vs. PBO Power: TPM vs. PBO Power: AMI vs. TPM Correct Winner AMI Better TPM Better Both None Prob. of Picking Winner Prob. of Picking Correct Winner 89% >99% 94% TPM 0% 93.6% 6.4% 0% 100% 100%

13 Notable Results Condition 38 : 50% PBO, 60% AMI, 70% TPM Demonstrates ~ 91% power to select TPM when difference between response rates is 10%, compared to 44% power in head to head comparison Individual Trials Decision Power Power: AMI vs. PBO Power: TPM vs. PBO Power: AMI vs. TPM Correct Winner AMI Better TPM Better Both None Prob. of Picking Winner Prob. of Picking Correct Winner 26% 89% 44% TPM 0.1% 70.5% 20.4% 9% 91% 91%

14 Results Cont. 4 Conditions with 50-80% power Condition 21: 45% PBO, 60% AMI, 50% TPM Correctly selects AMI 70% of the time Condition 27: 50% PBO, 60% AMI, 50% TPM Correctly selects AMI 51% of the time Condition 54: 55% PBO, 60% AMI, 70% TPM Correctly selects TPM 74% of the time Condition 58: 55% PBO, 70% AMI, 70% TPM Correctly selects both 76% of the time All show improvement over individual comparisons Power for individual comparisons between 0.8% and 64%

15 Results Cont. 3 Conditions with <50% power Condition 1: 40% PBO, 50% AMI, 50% TPM 37% probability of selecting a winner Condition 17: 45% PBO, 50% AMI, 50% TPM 11% probability of selecting any winner Condition 53: 55% PBO, 60% AMI, 50% TPM Probability of correctly selecting AMI is 43% Small treatment differences Benefits in these situation over individual trials Power for individual comparisons between 1.5% and 41%

16 Conclusion Combined 3 in 1 approach provides benefits above and beyond what can be achieved with separate hypotheses Clear winner in over 90% of conditions Power to determine winner was greater when results examined together as opposed to separate trials Confidence in using this a priori decision algorithm to inform clinicians Only considers tier 1 in decision algorithm

17 Acknowledgements The National Institute of Neurological Disorders and Stroke (NINDS) Principal Investigators: Dr. Andrew D. Hershey Dr. Scott W. Powers Clinical Coordinating Center at Cincinnati Children s Leigh Ann Chamberlin Leslie Korbee Data Coordinating Center at CTSDMC Dr. Chris Coffey Dixie Ecklund Jon Yankey

Questions? 18

19 References CHAMP Study Protocol and DSMB Materials Abu-Arefeh I, and Russell G. Prevalence of headache and migraine in schoolchildren. BMJ 309: 765-769, 1994. PMCID:2541010. Split W, and Neuman W. Epidemiology of migraine among students from randomly selected secondary schools in Lodz. Headache 39: 494-501, 1999. Bille B. A 40-year follow-up of school children with migraine. Cephalalgia 17: 488-491; discussion 487, 1997.